Trial Profile

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 26 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cladribine (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms CLADRINA

Most Recent Events

02 Dec 2024 Planned primary completion date changed from 30 Aug 2024 to 30 Aug 2026.
02 Mar 2024 Interim Results (n=39) assessing the clinical, biomarker, and safety data 12 months after initiation of CladT presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024
13 Sep 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com